North Wales-based Teva releases generic EpiPen

By

Its generic EpiPen, developed in a partnership with Antares Pharma, is carrying a price tag of $300, the same as the generic EpiPen sold by Mylan. (Photo courtesy of Teva)

Teva Pharmaceutical Industries, based in North Wales, released limited doses of a generic version of EpiPenAuto-Injector.

Its generic EpiPen, developed in a partnership with New Jersey-based Antares Pharma, is carrying a price tag of $300. That cost is the same as the generic EpiPen sold by Mylan, which makes the branded product as well. Mylan has come under criticism by government agencies and consumers because of price increases that have driven up the cost of the branded EpiPen injector from less than $100 to more than $600 during the past decade, writes John George in the Philadelphia Business Journal.

[uam_ad id=”54865″]

 


Brendan O’Grady, a Teva executive vice president and head of its North America commercial operations, said the epinephrine injection delivered by its product is designed for patients who may experience life-threatening allergic emergencies. “We’re fully dedicated toward ensuring additional supply in 2019,” O’Grady said.

The FDA in August OK’d Teva’s application to market the first generic EpiPen domestically.

Teva’s product uses Antares Pharma’s Vibex auto injector technology. Antares (NASDAQ: ATRS) of Ewing, N.J., previously entered into an exclusive license, development and supply agreement with Teva for an epinephrine auto injector to be marketed in the United States. Teva is responsible for distribution of the final product, for which Antares will receive royalties on net sales.

To read the complete story click here.

[uam_ad id=”54875″]

Stay Connected, Stay Informed

Subscribe for great stories in your community!

"*" indicates required fields

Hidden
MT Yes
This field is for validation purposes and should be left unchanged.
Advertisement